In the previous prospectus $5M was supposed to take AMD through in vivo proof of concept. Now, $4M is supposed to take AMD through in vivo proof of concept, IND and start of a clinical trial.
I know that being critical of management is not popular on HC but, come on, this is just finger in the wind budgeting and how can that be good management?
- Forums
- ASX - By Stock
- BLT
- Updated listing price
Updated listing price, page-26
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)